Drug intelligence / Profile preview

CHI-554

Development stage: Phase 1
Lead developer: Auburn University
Modality: Small Molecules
Administration: Oral

Overview

CHI-554 is an investigational drug currently being evaluated in a Phase 1, randomized, double-blind clinical trial to assess its safety, tolerability, and effects when co-administered with alcohol in healthy adults. The study is sponsored by Auburn University. The specific mechanism of action and primary therapeutic indication for CHI-554 have not been disclosed in the available public sources. However, there is mention of its evaluation in the context of fear modulation or anxiety-related research.

Beyond the preview

Go deeper on CHI-554.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHI-554.

Explore the full profile